Drägerwerk AG & Co. KGaA (ETR:DRW3) Trading 0.8% Higher - Here's Why

Key Points

• Drägerwerk AG & Co. KGaA shares increased by 0.8%, reaching a last trading price of €67.10 ($78.02), despite a significant drop in trading volume by 43%.
• The company has a market capitalization of $1.17 billion and notable financial ratios, including a PE ratio of 11.10 and a beta of -0.31.
• Drägerwerk specializes in medical and safety technology, providing equipment and services for various sectors, including emergency medicine and industrial safety.

Drägerwerk AG & Co. KGaA (ETR:DRW3 - ) shares rose 0.8% during trading on Friday . The stock traded as high as €67.20 ($78.14) and last traded at €67.10 ($78.02). Approximately 19,153 shares were traded during trading, a decline of 43% from the average daily volume of 33,804 shares. The stock had previously closed at €66.60 ($77.44).

Drägerwerk AG & Co. KGaA Stock Performance

The firm has a 50-day moving average price of €68.46 and a 200 day moving average price of €62.53. The firm has a market capitalization of $1.17 billion, a PE ratio of 11.10, a price-to-earnings-growth ratio of 1.24 and a beta of -0.31. The company has a quick ratio of 0.81, a current ratio of 1.89 and a debt-to-equity ratio of 20.57.

About Drägerwerk AG & Co. KGaA

Drägerwerk AG & Co KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.